Related Experiment Videos
[Guidelines for antiarrhythmic therapy]
1Cardio-pulmonary Division, Keio University School of Medicine.
Insights
Recent advancements in arrhythmia therapies include improved diagnostics, drugs, and devices like pacemakers. This review covers new US and Japanese guidelines for antiarrhythmic drugs, atrial fibrillation management, and device therapy.
Area of Science:
- Cardiology
- Electrophysiology
Context:
- Therapies for cardiac arrhythmias have significantly advanced.
- Progress is driven by electrophysiological knowledge, diagnostic techniques, and novel antiarrhythmic drugs and devices.
Purpose:
- To review current guidelines for managing cardiac arrhythmias.
- To provide an overview of recent advancements in antiarrhythmic drug and device therapies.
Summary:
- The review discusses the evolution of arrhythmia treatment strategies, including the impact of the Cardiac Arrhythmia Suppression Trial (CAST) and the Sicilian Gambit.
- It highlights the publication of three American Heart Association (AHA) guidelines in the United States.
- Japanese guidelines for antiarrhythmic drugs, atrial fibrillation management, and antiarrhythmic devices are also presented.
Impact:
- Provides a consolidated overview of contemporary arrhythmia management strategies.
- Facilitates understanding of updated clinical practice guidelines for healthcare professionals.
- Informs the clinical application of advanced antiarrhythmic drugs and devices.
Abstract:
Recentry, therapies for arrhythmias have been extremely advanced by accumulation of electrophysiological knowledge, improvement of diagnostic technique, and development of antiarrhythmic drugs and devices(pacemakers, catheter ablation and implantable cardioverter-defibrillators). After the report of the CAST(Cardiac Arrhythmia Suppression Trial), the Sicilian Gambit was presented as new strategies of drug therapy. Now in the United States, three AHA guidelines were published. Besides in Japan 'the guidelines for antiarrhythmic drugs' based on the Sicilian Gambit was published. 'The guidelines for management of Atrial fibrillation' and 'the guidelines for antiarrhythmic devices' were also reported. Here, these guidelines are reviewed.